EvitarTM - Expands Post-Surgery Adhesion Market in Laparoscopy Surgery

Ready to address $2.5 billion US Global Market

Current literature suggests that addressing hypoxia and shifting anaerobic metabolism to aerobic metabolism could be a viable strategy to preventing post surgery adhesions. Evitar™ is a proprietary aqueous formulation of naturally occurring amino acids. In preclinical models, when it is administered into the peritoneal cavity at the time of surgery it has been demonstrated, through the use of known peritoneal inflammatory biomarkers, to prevent post-surgery adhesions or fibrosis.


I believe the approach has potential to set a new standard of care in gynecology pelvic surgeries. For me it is important that it is not a barrier or medical devices which are not that effective. Read More  

Dr. James Greenberg Vice Chair Obs and Gyne, Brigham and Women's, Harvard Medical School


 


Learn More

View our R&D Pipeline

  • TTX-330 Spinal

    TTX-330 Spinal is a drug and bioresorbable polymer combination that helps reduce peridural fibrosis following spinal surgery.

  • TTX-332 TRANSPLANT DELAYED GRAFT FUNCTION (DGF)

    Healthcare leaders are stepping up efforts to diagnose and treat DGF. TTX-332 is a promising therapeutic strategy for the prevention of DGF, an area of high unmet medical need.

Our TEAM

  • I believe the approach has potential to set a new standard of care in gynecology pelvic surgeries. For me it is important that it is not a barrier or medical devices which are not that effective... Read More

    Dr. James Greenberg Vice Chair Obs and Gyne, Brigham and Women's, Harvard Medical School
View All Success Stories

MeEt Us

View our upcoming events

View All Events

  • Urmonderbaan 22 (Gate 2) 6167 RD Geleen Netherlands
    PO Box 18 6160 MD Geleen Netherlands

  • info@templerx.com

© 2017 Temple Therapeutics BV. All Rights Reserved

Website Design & Developed by 2Web Design